Creatine Transporter Deficiency (CTD) is a rare genetic disorder caused by mutations in the SLC6A8 gene, which encodes the creatine transporter responsible for cellular uptake of creatine.

The agreement gives Merck exclusive ex-US rights to ompenaclid – an oral inhibitor of the creatine transport channel SLC6A8 – as well as options to co-develop and co-promote the drug in the US ...